On Tuesday\u2019s edition of Market Catalysts<\/em>, host Julie Hyman spotlighted several market movers that captured Wall Street\u2019s attention amid a volatile trading session. The day\u2019s highlights ranged from fierce competition in the pharmaceutical industry to dramatic turns in biotech and automotive stocks.<\/p>\n\n\n\n Pfizer (PFE)<\/strong> and Novo Nordisk (NVO)<\/strong> both raised their bids to acquire biotech firm Metsera (MTSR)<\/strong>, signaling intensifying interest in the company\u2019s pipeline of metabolic and rare disease treatments. The bidding war underscores large pharmaceutical companies\u2019 renewed focus on acquiring innovative drug developers to bolster long-term growth, particularly in metabolic and obesity-related therapies \u2014 a sector that\u2019s rapidly expanding thanks to blockbuster drugs like Ozempic and Wegovy.<\/p>\n\n\n\n Meanwhile, shares of Sarepta Therapeutics (SRPT)<\/strong> plunged sharply after one of its key drug trials failed to meet primary endpoints. The setback was a significant blow to investor confidence, as Sarepta had been banking on positive data to support broader use of its gene therapy for muscular dystrophy. The disappointing results wiped out much of the company\u2019s recent gains and reignited concerns over the high risks inherent in experimental biotech investments.<\/p>\n\n\n\n In contrast, Hertz Global Holdings (HTZ)<\/strong> stunned investors with a surprise quarterly profit, sending its shares soaring. The rebound came as the car rental company benefited from improved fleet utilization, stabilized electric vehicle costs, and strong travel demand heading into the holiday season.<\/p>\n\n\n\n Together, these developments painted a dynamic picture of the markets \u2014 where big pharma\u2019s dealmaking, biotech\u2019s volatility, and unexpected corporate turnarounds continue to drive investor sentiment.<\/p>\n\n\n\n